SAN FRANCISCO and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief executive officer, Nima Farzan, will participate in the Piper Sandler Heartland Summit as part of the panel “Healthcare Politics: FDA Proposals from Optimus, to ORBIS to RTOR and CONFIRM – How Might These Proposals Impact Oncology Drug Development and Implications?” on Thursday, September 22, 2022 at 11:30 a.m. C.T.

Continued here:
Kinnate Biopharma Inc. to Participate in the 2022 Piper Sandler Heartland Summit

Dr. Hamed has over 20 years of anti-infective experience and has spearheaded the global development and approval of multiple anti-infective products Dr. Hamed has over 20 years of anti-infective experience and has spearheaded the global development and approval of multiple anti-infective products

Follow this link:
Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

Announced a $130 million registered direct offering and concurrent private placement priced at-the-market

See the rest here:
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress

John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, Joins as a Strategic Advisor John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, Joins as a Strategic Advisor

More:
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

-- Combined Company to Trade on Nasdaq Under Ticker “SYRS” ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock --CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME’s special meeting, TYME’s stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the “Merger Agreement”), pursuant to which a direct, wholly owned subsidiary of Syros will merge with and into TYME, with TYME surviving as a wholly owned subsidiary of Syros (the “Merger”). At Syros’ special meeting, Syros’ stockholders also voted in favor of all proposals, including the proposal to approve the issuance of shares of Syros’ common stock to holders of TYME’s common stock in connection with the Merger and to certain of Syros’ investors in connection with a concurrent private investment in public equity (“PIPE”) financing.

Read more from the original source:
Syros and Tyme Technologies Announce Stockholder Approval of Merger

WOBURN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the International Symposium on Biopolymers (“ISBP”) 2022 Conference. The event is taking place September 12 through September 16, 2022 in Sion, Switzerland.

Link:
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advancements in Producing PHA Bioplastic in Camelina at the ISBP 2022...

All director nominees reelected for the coming yearAll other proposals also approved by shareholders

See the article here:
Medexus Holds Annual Meeting of Shareholders and Announces Election of Board of Directors

Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease Patients Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease Patients

Here is the original post:
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022

LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual meetings with institutional investors as part of the Lytham Partners Fall 2022 Investor Conference. The event is taking place virtually on September 28 - 29, 2022.

Read the original here:
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference

nicox saInterim Consolidated statement of Comprehensive Income

More:
Nicox Provides First Half 2022 Business Update and Financial Results